Navigation Links
Avery Biomedical Devices, Inc. Appoints Elefteriades to its Board of Directors
Date:10/15/2007

COMMACK, N.Y., Oct. 15 /PRNewswire/ -- It is with great privilege that Avery Biomedical Devices, Inc. (ABD) announces the appointment of John A. Elefteriades, M.D., F.A.C.S. to its Board of Directors.

Dr. Elefteriades is the William W.L. Glenn Professor of Cardiothoracic Surgery and Chief of Cardiac Surgery at Yale University and Yale-New Haven Hospital. He serves as Co-Director of the Yale-New Haven Hospital Heart Center. He is recognized consistently in America's Top Doctors published by Castle Connolly. He serves on the Editorial Boards of the American Journal of Cardiology, Cardiology, The International Journal of Angiology, The Journal of Cardiac Surgery, and The Journal of Thoracic and Cardiovascular Surgery, among others. He has served on the Board of Governors of the American College of Cardiology and as President of the International College of Angiology. He has recently served on a steering committee for future research at the National Science Foundation.

Dr. Elefteriades has conducted award-winning pioneering research in cardiac surgery and has been instrumental in the development and testing of many medical devices, including ABD's phrenic nerve stimulator. He has published over 200 scientific papers and dozens of book chapters, as well as several textbooks of medicine and surgery. For the lay public, he has authored the recently published Your Heart: An Owner's Guide and the upcoming The Women's Heart: An Owner's Guide.

Linda Towler, CEO, states, "We are honored to have Dr. Elefteriades join our Board of Directors. His experience and expertise will be invaluable to the future growth of ABD."

Dr. Elefteriades states, "It is a privilege to serve on the Board of Directors of ABD. This company has served the world's need in diaphragm pacing. Exciting new products are under development in this and related arenas as well. I look forward to providing medical and surgical input to the Board."

ABOUT ABD

Avery Biomedical Devices, Inc. (ABD) is a privately-held biomedical device manufacturer located on Long Island, New York. It produces the breathing pacemaker: an implanted phrenic nerve stimulator which is used to free many quadriplegic and central hypoventilation patients from mechanical ventilation. Through its wholly-owned subsidiary, ABD Custom Manufacturing, Inc., ABD manufactures high-quality platinum contact electrodes for research projects, clinical trials and commercially distributed medical devices.

ABD is ISO-9001 certified, ISO-13485 compliant, and an FDA registered manufacturer of Class III medical devices.

Should you know a patient with quadriplegia, central sleep apnea or other condition that may benefit from a breathing pacemaker, or if you are interested in our ABD Custom products, please contact us.

CONTACT

Kenneth R. Aron, V. P. Sales & Marketing

631-864-1600

http://www.averybiomedical.com


'/>"/>
SOURCE Avery Biomedical Devices, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. UW Academic ADL Co-Lab joins worldwide effort against slavery
2. Biomedical engineering conference invites manufacturers
3. Manufacturing partnership will move into biotech and biomedical spaces
4. Biomedical Alliance about more than stem cells
5. Doyle seeks $2.5M for biomedical alliance
6. Students will show off biomedical devices to professors and investors
7. Biomedical alliance marks first full year
8. UW Biomedical Engineering awarded $2.9 million research grant
9. Having two biomedical tech centers in Wisconsin will help the state
10. New biomedical institute aims to unite business and academia in SE Wisconsin
11. Wisconsin publicly traded biomedical companies report gains this quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 ... $7M Series B financing, adding an additional $3M from ... by Mesa Verde Venture Partners and other strategic partners ... directed towards further accelerating commercial adoption of their flagship ... test and expanding the Paradigm cancer registry. ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... 15, 2017 Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, will host ... at 8:00 AM EST on Thursday, February 16, 2017 ... program, the recently announced closing of a $10.5 million ... To participate in the live call and take ...
Breaking Biology Technology:
(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
Breaking Biology News(10 mins):